Pertzov B, et al. - Researchers tested mepolizumab's (a monoclonal antibody that targets the interleukin 5 pathway) safety and efficacy in a real-world cohort of patients with severe eosinophilic asthma in this clinical prospective observational trial. Participants were all patients aged > 18 years who received therapy with mepolizumab between March 2016 to March 2019 at Rabin Medical Center. Increase in FEV1 by ≥ 200 ml and/or decline in exacerbation rate of ≥ 50% and/or discontinuance of oral corticosteroids (OCS) therapy or ≥ 50% reduction in dosage were the composite primary outcome measures that were assessed. Overall sample included 61 patients, among these, the primary outcome was achieved by 50 (82.0%). An improvement in quality of life was experienced by 49 patients (80%). The documented adverse events were minor. Overall, findings revealed the good tolerability of mepolizumab treatment in this patient cohort, as well as its ability to significantly lower the exacerbation rate and OCS dependence. Response to treatment was within six months. A sustained treatment effect was noted over time.